More than a decade after first earning the FDA’s sign-off for its Zio ECG patch, iRhythm is still churning out data to prove beyond a shadow of a doubt the heart monitor’s ability to spot atrial fibrillation and other arrhythmias as early as possible. The latest bit of proof came in the form of a trio of studies presented at the American College of Cardiology’s annual scientific meeting.
The research shows that the two-week, artificial intelligence-powered Zio system doesn’t just aid in diagnosing afib in patients with a standard risk level, but also helps monitor higher-risk patients after cardiac and other procedures, potentially saving hospitals time, money and bed space.
“We are excited that these new data continue to demonstrate that Zio’s clinical accuracy is beneficial in directing patient care across a variety of settings while improving clinical workflows and hospital capacity. We are also particularly encouraged to see further evidence of Zio’s ability to support early detection and diagnosis of AF in moderate-risk populations,” said Dietra Jones, iRhythm’s executive VP of clinical operations.
Alfa Chemistry, a leading provider of chemical and materials solutions, has recently announced the expansion of its product portfolio by offering a wide range of high-quality alloys, including ferric, nickel, aluminum, titanium, and magnesium alloys. With its outstanding expertise and commitment to customer satisfaction, Alfa Chemistry aims to cater to the diverse needs of industries worldwide.
The newly introduced alloys by Alfa Chemistry have attracted considerable attention in various sectors, owing to their...
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device
Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus
Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce the successful first implant of the Company’s...
After struggling to conceive a child for what felt like ages, Miranda of Moncks County, South Carolina finally fell pregnant - a miracle that quickly turned into horror when she delivered at 24 weeks in late 2015. At just 1 pound and 12 ounces, her son, Sutton, arrived with life-threatening health issues, including hydrocephalus - a neurological disorder caused by an abnormal buildup of cerebrospinal fluid in the brain that affects more than one million Americans.
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has launched a new line of Locust Bean Gum with advanced technical platforms to help scientists advance biopharmaceutical research.
Over the past few decades, researchers have been working on developing delivery systems that can reduce side effects while improving efficacy. Natural polymers are used in a wide range of pharmaceutical formulations, including solid monolithic matrix systems, implants, films, beads,...
Microsphere formulation has been highlighted as a promising dosage form in clinical practice due to its ability to significantly improve patient convenience and compliance. As a trustworthy partner in the field of pharmaceutical formulation, CD Formulation has newly introduced a range of raw materials for the production of microspheres and microneedles, which are highly expected to advance innovative drug delivery systems and non-invasive procedures.
Compared with conventional formulations, microspheres enable...
Customer comments
No comments were found for ACC: iRhythm`s Zio ECG patch catches arrhythmia in older patients, after TAVR implants. Be the first to comment!
